Cisplatin + Pembrolizumab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvar Cancer
Conditions
Vulvar Cancer, Vulvar Squamous Cell Carcinoma
Trial Timeline
Jul 29, 2020 → Jan 30, 2028
NCT ID
NCT04430699About Cisplatin + Pembrolizumab
Cisplatin + Pembrolizumab is a phase 2 stage product being developed by Merck for Vulvar Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04430699. Target conditions include Vulvar Cancer, Vulvar Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04430699 | Phase 2 | Active |
Competing Products
7 competing products in Vulvar Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 52 |
| Estradiol | Sun Pharmaceutical | Phase 3 | 77 |
| Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark) | Glenmark Pharmaceuticals | Phase 3 | 77 |
| Cardunolizumab | Innovent Biologics | Phase 2 | 51 |
| AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin | Akeso | Phase 2 | 51 |
| AVA6103 | Avacta Group | Phase 1 | 25 |
| VGX-3100 + Imiquimod 5% Cream | Inovio Pharmaceuticals | Phase 2 | 44 |